For how we live.
A systematic review of the Syrian crisis and infectious disease in Lebanon names overcrowding, poor sanitation and blocked healthcare access — not the presence of refugees themselves — as the reported drivers.
VPM1002 did not show non-inferiority to BCG for preventing tuberculosis infection in a phase 3 trial across sub-Saharan Africa. Far fewer infections occurred than planned, leaving the comparison unresolved.
The estimate covers 2000 to 2023 and 108 countries. It is a counterfactual model, not a measured saving, and it lands as the US and other donors debate cutting the disease-specific funding it credits.
The Lancet Global Health paper that produced this month's headline number also produced a larger one: 22.6 million additional deaths by 2030 if defunding deepens. The distinction matters more than the figure.
Washington intends to provide up to $792 million over five years. Malawi commits the rest — and the money is meant to flow through the government rather than NGOs.
Shared cell time raises transmission odds sharply — six months of it doubles them. But cell-level exposure explains only part of the genomic clustering, which undercuts contact tracing as a strategy.
WHO's Global Tuberculosis Report 2025 counts 10.7 million people ill and over 1.2 million dead last year. Available funding is US$5.9 billion against a US$22 billion annual target.
A TB vaccine financing plan, six target product profiles for children's cancer drugs, and a paediatric research agenda. All three are attempts to specify a product before a market decides to build it.
Across 165 clinics in four African countries, HIV testing fell by up to 35% and treatment starts by up to 32%. Most services had not returned to baseline two months after the orders were lifted.
IHME's annual accounting puts development assistance for health at less than half its 2021 peak, with no recovery forecast to 2030. A companion model estimates what that means for tuberculosis.
A Global Burden of Disease analysis of 204 countries finds 15.7 million children received no DTP dose in 2023, more than half of them in eight countries, and only one of three target vaccines on track for 2030.